Subscribe
Be the first with the news that moves the market- The Green Organic Dutchman (TSX:TGOD) has received a cannabis research license from Health Canada
- Valid for five years, it will eliminate reliance on third party companies and organisations
- The operational streamlining is expected to reduce costs and accelerate the rate of product development
- The company’s Cannabis 2.0 products are also expected to launch later this year
- Shares in the company are currently up 5.56 per cent to C$0.57, with a market cap of C$178.26 million
The Green Organic Dutchman (TSX:TGOD) has received a cannabis research license from Health Canada.
Based in Ontario, the company is a leader in the organic cultivation of premium cannabis products.
With receipt of the license, The Green Organic Dutchman will be free to commence in-house product development and testing, eliminating reliance on third parties.
The more streamlined approach is expected to reduce costs and increase the efficiency of operational activities, while adding further capabilities in quality control and product consistency.
The company’s CEO, Brian Athaide, knows that consumers are aware of different grades in commercial cannabis products.
“We want to ensure that TGOD continues to go to market with consumables that bear a seal of premium quality that they can trust,” he said.
“By leveraging the expertise of our in‐house Science and Marketing teams, we are able to optimize costs and accelerate our speed to market.”
“In parallel,” he continued, “we are also layering on additional quality control measures ensuring a high level of consistency across all our product lines.”
The Green Organic Dutchman is firmly set in the CBD flower and oil segment.
However, the company plans to leverage the new license to complete and bring to market its new ‘Cannabis 2.0’ products.
The beverages, edibles, vapes and topicals that make up the new generation of cannabis consumables are expected to launch later this year.
The Green Organic Dutchman listed in early May 2018, raising more than C$115 million in one of the largest Canadian cannabis IPOs in history.
Shares in the company are currently up 5.56 per cent to C$0.57, with a market cap of C$178.26 million.
